Table 2. Rates of SVR for patients with compensated cirrhosis HCV genotype 2–4 (phase III/IV studies).

HCV Genotype	Regimen	Duration	Patients	SVR rate	Study (reference)
HCV genotype 3	DCV – SOF	12 weeks	Naïve and TE	58–97%	ALLY-3 43
HCV genotype 2 HCV genotype 3	SOF + RBV	12 weeks 12 weeks	Naïve	91% 34%	FISSION 40
HCV genotype 2 HCV genotype 3	SOF + RBV	12 weeks 12 weeks	Naïve	94% 21%	POSITRON 39
HCV genotype 3 HCV genotype 2 HCV genotype 3	SOF + RBV	24 weeks 12 weeks 24 weeks	Naïve TE TE	92% 78% 62%	VALENCE 92
HCV genotype 2 HCV genotype 3 HCV genotype 3	SOF + RBV	16 weeks 24 weeks 16 weeks 24 weeks 16 weeks 24 weeks	TE Naïve TE	87% 100% 57% 82% 47% 76%	BOSON STUDY 44
HCV genotype 2	SOF + RBV	12 weeks	Naïve TE	67% 76%	Trio Network 85
HCV genotype 2 HCV genotype 3	SOF + RBV SOF + RBV	12 weeks 16 weeks 12 weeks 16 weeks	TE TE	60% 78% 19% 61%	FUSION 39
HCV genotype non-1	SOF – VPV	12 weeks	Naïve and TE	100%	ASTRAL-1 45
HCV genotype 2	SOF – VPV	12 weeks	Naïve and TE	100%	ASTRAL-2 93
HCV genotype 3	SOF – VPV	12 weeks	Naïve and TE	91%	ASTRAL-3 93
HCV genotype 3	DCV – SOF + RBV	12 weeks 16 weeks	Naïve and TE	83% 89%	ALLY-3+ 94

a. Abbreviations: DCV, daclatasvir; HCV, hepatitis C virus; RBV, ribavirin; SOF, sofosbuvir; SVR, sustained virological response; TE, treatment-experienced; VPV, velpatasvir